VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2022 | Beyond anthracyclines and trastuzumab: cardiotoxicity of novel agents

The cardiotoxicity of anthracyclines and trastuzumab in the treatment of breast cancer have been well elucidated, however there is little information surrounding the cardiovascular impact for more recent novel agents. Susan Dent, MD, FRCPC, Duke University School of Medicine, Durham, NC, discusses the cardiovascular impact of newer novel agents including CDK4/6 inhibitors and immune checkpoint inhibitors. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter